CLAIMS

1. A method for detecting specific target cells in cell
suspensions of mixed cell populations and in fluid systems
containing mixed cell populations, and in single cell suspen-
sions prepared from solid tissues, characterized by comprising
the following steps:

1.1. coating, by a per se known procedure, paramagnetic
particles or beads with either, a) antibodies, or antibody
fragments directed against membrane structures specifically
expressed on target-cells and not on non-target-cells in the
cell mixture or;
b) antibodies, preferably polyclonal anti-mouse or monoclonal
rat anti-mouse antibodies or anti-human antibodies, capable of
binding to the Fc-portions of the said antibodies, directed
against the membrane structures; and

1.2.1. mixing the target-cell-associating antibodies (murine or
human) which is attached to the said particles or beads, or
attached to the beads pre-coated with anti-mouse or antihuman
antibodies recognizing the Fc-portions of the target-
associating antibodies, with the cell suspension containing the
target-cells, or,

1.2.2. mixing free target-cell-associating antibodies with the
cell suspension containing the target cells and incubate this
mixture for 5-10 min to 2 h, preferably 30 min, at a
temperature between 0°C and 20°C, preferably 4°C under gentle
rotation, and;

1.3. incubating the mixture of the cell suspension and
target-associating antibodies attached to paramagnetic
particles or beads (1.2.1), or paramagnetic particles or beads,
precoated with anti-mouse or anti-human antibodies recognizing
the Fc-portion of the target-associating antibodies, to the
mixture of incubated free target associating antibody and cell
suspension (1.2.2.), and incubating, for 5-10 min to 2 h,

AMENDED SHEET

preferably 30 min, at a temperature between 0˚C and 25˚C, preferably 4˚C, under gentle rotation, and;

1.4.1. if the target cell population is contained in blood or bone marrow aspirates the hydrophobic forces associated with antibody-coated particles are reduced by pre-incubating the antibody-coated particles and the cell suspension with mild detergents in suitable concentrations, e.g. Tween 20(TM) in concentrations less than 0.1% for 30 min at 4°C, and/or

1.4.2. by incubating the cell suspensions, untreated or pretreated with formalin, alcohol or other fixatives, with other antibodies or antibody fragments binding to extracellular or intracellular molecules present in the target cells and the antibodies used are labeled in advance by peroxidase, alkaline phosphatase, or other enzymes permitting visualization of the binding by addition and incubation with relevant substrates, or

1.4.3. the antibody fragments are biotinylated and the binding visualized when adding the incubating with avidin complexed to peroxidase, alkaline phosphatase, or other enzymes, with addition and incubation with relevant substrates, or

1.5.1. subjecting the incubated paramagnetic particle-antibodies-cell mixture (1.3) to a magnetic field if the density of target-cells is low, or if the ratio of target cell/total cells in the cell mixture is low ($\leq$ 1 %) and then examining and counting the stained or unstained particle-target-cell complexes in the cell suspension, using a micropscope and/or a suitable cell/particle counting device, or,

1.5.2. examining and counting the target-cells in the incubated mixture of paramagnetic particles, antibodies and cell mixture (1.3), or in the case when the antibodies or antibody fragments are conjugated to non-paramagnetic particles that can be visualized directly because of colour or through enzymatic activation, using a microscope and/or a suitable cell/particle

counting device if the ratio of target-cells/total cells in the cell suspension is adequate (> 1 %).

2. Method according to claim 1, characterized by directing the antibody or fragments thereof against the antigens in normal, living cells, such as liver hepatocytes, Kupffer cells and endothelial cells type 1 and 2 and Clara cells of the lung, endothelial cells of specific organs, pancreatic exocrine and endocrine cells, kidney tubule cells, bladder epithelial cells, brain glial and ependymal cells, bladder and prostate epithelial cells, ciliated cells of airways, different subpopulations of mucosal cells in the gastrointestinal tract, pituitary cells, and other endocrine cells in various hormone-producing organs.

B

3. Method according to ~claim 2~ one of the preceding claims, characterized by using as the said target-cell antibody an antibody which is reactive with antigens present on subpopulations of normal cells and oncogenic products expressed on the membrane of normal tissue cells.

B

4. Method according to ~claim 3~ one of the preceding claims, characterized by using as the said positive selecting antibody, an antibody which is directed against growth factor receptors on the membrane of normal cells, for example the EGF-receptor, PDGF (A and B) receptor, insuline receptors, insuline-like receptors transferrin receptor, NGF and FGF receptors.

B

5. Method according to ~claim 4~ one of the preceding claims, characterized by using an antibody directed against the group of integrins and other adhesion membrane molecules, and MDR proteins in normal cells.

B

6. Method according to ~claim 5~ one of the preceding claims, characterized by directing the antibody or fragments thereof against antigen or receptors in cells with abnormal developmental patterns, preferably such as primary and metastatic cancer cells.

AMENDED SHEET

β 7. Method according to ~~one of the preceding claims~~ *claim 6*,
characterized by using as the said target-cell associating
antibodies, antibodies of the IgG isotype, or $F(ab')_2$ or $F(ab)$
fragments, or IgM, or fragments of IgM.

β 8. Method according to ~~one of the preceding claims~~ *claim 7*,
characterized by preparing the mentioned cell suspension from
mixed cell populations comprising mammalian tissues, for
examples human bone marrow and peripheral blood, from pleural
and peritoneal effusions, other body fluids, for example urine,
cerebrospinal fluid, semen, lymph, or from solid tumors in
normal tissues and organs, for example liver, lymphatic nodes,
spleen, lung, pancreas, bone tissue, central nervous system,
prostatic gland, skin and mucous membranes.

β 9. Method according to ~~one of the preceding claims~~ *claim 8*,
characterized by that the antibody or antibody fragments is
directed against groups of antigen determinants, such as those
listed in the Table 1 of the specification.

β 10. Method according to ~~one of the preceding claims~~ *claim 9*,
characterized by using as the said target-cell antibody an
antibody or antibody fragment which is directed against growth
factor receptors and oncogene products expressed on the
membrane of malignant cells, for example insuline receptors,
insuline-like receptors and FGF receptors in addition to those
listed in Table 1 of the specification.

β 11. Method according to ~~one of the preceding claims~~ *claim 10*,
characterized by using an antibody or antibody fragment
directed against the group of integrins, other adhesion
membrane molecules and MDR proteins in abnormal cells as listed
in Table 1.

β 12. Method according to ~~one of the preceding claims~~ *claim 11*,
characterized in that the used antibodies, antibody fragments

or combination of these are directed to the antigen determinants as listed in Table 1 of the specification.

Claim 12

β 13. Method according to ~~one of the preceding claims~~, characterized by using as the said antibody an antibody which is reactive with antigens present on abnormal cells, for example breast, ovarian and lung carcinoma cells, melanoma, sarcoma, glioblastoma and cancer cells of the gastrointestinal and genitourinary tract, and of the reticuloendothelial system, and/or target-cells associated with non-neoplastic diseases, such as cardiovascular, neurological, pulmonary, autoimmune gastrointestinal, genitourinary, reticuloendothelial and other disorders.

β 14. Use of the detection method according to ~~one of the~~
β ~~preceding claims~~, for isolation of target-cells, whereby the complex of cells and the paramagnetic particles are exposed to a magnetic field and the resulting magnetically aggregated cells are further subjected to biological, biochemical and immunological examinations, including also characterisation of specific genes at the DNA, mRNA and protein level, including polymerase chain reaction (PCR) and reverse transcriptase PCR.

Claim 13

15. Use of the method for detection of specific target-cells
β according to ~~to one of the preceding claims~~, whereby it is established in vitro cell cultures from the separated paramagnetic particle-target-cell-complexes, and/or for inoculation into immunodeficient animals, preferably to establish human tumor xenografts in the said animals.

Claim 14

β 16. Kit for performing the method according to ~~one of the~~
β ~~preceding claims~~, characterized by that it comprises;
1, specific antibodies or antibody fragments directed to the antigen receptors on the wanted target-cells, where said antibody or antibody fragment is bound or can be bound to included paramagnetic particles, without removing their antigen-binding ability, and/or

Claim 15

AMENDED SHEET

2,   paramagnetic particles precoated with specific anti-Fc antibodies, preferably polyclonal anti-mouse, or monoclonal rat anti-mouse, or anti-human antibodies, capable of binding to the Fc portions of the target-cell associating antibodies, and specific free target-cell antibodies, and/or

3,   paramagnetic particles precoated with specific anti-Fc antibodies, preferably polyclonal anti-mouse, or monoclonal rat anti-mouse, or anti-human antibodies, capable of binding to the Fc-portions of the target-cell associating antibodies, bound to specific anti-target-cell antibodies, and/or

4,   other specific antibodies or antibody fragments directed against antigens/receptors within or on the wanted target cells, where said antibodies or antibody fragments are conjugated to biotin, peroxidase, alkaline phosphatase, or other enzymes, or where said antibodies or antibody fragments are bound to non-paramagnetic particles with specific colours or with bound enzymes such as peroxidase and alkaline phosphatase.

add B'

add C'

add D'

add E'